Over the last 15 years on this grant, we have established that biologically active, CDR grafted humanized IgG, novel radioconjugates and toxin conjugates, many based on the anti-CD33 Ig HuM195, can be constructed, characterized, and translated into successful clinical trials in patients with AML. Most recently, we described a novel class of radio-immuno-pharmaceutical, "a targetable atomic nanogenerator," with exceptional potency that has entered human clinical phase I use and that already shows anti-leukemia activity at the lowest doses. The long-term goals of the program have been to understand and improve alpha particle immunotherapy. We are now exploring the biology and radiobiology of the tumor and its environment, especially its vasculature, to better understand how to make more effective alpha-emitting agents. In the current proposal, we plan to build on this scientific foundation in targeted radioimmunotherapeutics: (1) to answer several new questions that have emerged out of our previous work targeting vasculature;(2) to explain the mechanisms of action and resistance to antibody targeted alpha-particle irradiation. Throughout this work, as before, we aim to ultimately provide therapeutic agents and concepts for their appropriate use and direct application to human clinical trials. The potency and short range of alphas makes them appealing agents for selective killing of tumor neovasculature. Initial studies showed that we could deplete and normalize residual tumor vessels in animal models with effective anti-cancer activity.
In Aim 1, we plan to explore how to best utilize this finding to optimize combining alpha immunotherapy to neovasculature with agents directed to the tumor cells themselves. We also explore mechanisms by determining how the properties of the subsequent anti-tumor agents affect kinetics and tumor therapy outcomes following vessel targeting.
In Aim 2, we will examine potential mechanisms of cellular resistance to alpha particle damage including: a) DNA damage sensors and transducers or apoptosis mediators or cell cycle checkpoints that distinguish alpha-resistant from sensitive cells or affect alpha sensitivity;b) DNA repair or damage mitigation mechanisms. Understanding this critical biology should allow better strategies to avoid normal cell killing and tissue damage, while enhancing tumor cell kill.

Public Health Relevance

Recently, we described a novel class of radioimmunopharmaceutical, "a targetable atomic nanogenerator," with exceptional potency that has entered human use with anti- leukemia activity already evident at the lowest doses in its initial phase 1 trial. The long- term goals of the project are to develop simple targeting vehicles that kill via alpha particle emission and that make use of our understanding of the tumor's response to alpha particle damage.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Muszynski, Karen
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Sheth, A; Escobar-Alvarez, S; Gardner, J et al. (2014) Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers. Cell Death Dis 5:e1152
Dubrovsky, Leonid; Pankov, Dmitry; Brea, Elliott Joseph et al. (2014) A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood 123:3296-304
Maguire, William F; McDevitt, Michael R; Smith-Jones, Peter M et al. (2014) Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for ?-particle radioimmunotherapy of cancer. J Nucl Med 55:1492-8
Villa, Jennifer C; Chiu, Danica; Brandes, Alissa H et al. (2014) Nontranscriptional role of Hif-1? in activation of ?-secretase and notch signaling in breast cancer. Cell Rep 8:1077-92
Veomett, Nicholas; Dao, Tao; Liu, Hong et al. (2014) Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. Clin Cancer Res 20:4036-46
Mallikaratchy, Prabodhika; Gardner, Jeffery; Nordstrøm, Lars Ulrik R et al. (2013) A self-assembling short oligonucleotide duplex suitable for pretargeting. Nucleic Acid Ther 23:289-99
Mulvey, J Justin; Villa, Carlos H; McDevitt, Michael R et al. (2013) Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery. Nat Nanotechnol 8:763-71
Scheinberg, David A; McDevitt, Michael R; Dao, Tao et al. (2013) Carbon nanotubes as vaccine scaffolds. Adv Drug Deliv Rev 65:2016-22
Dao, Tao; Yan, Su; Veomett, Nicholas et al. (2013) Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 5:176ra33
Mallikaratchy, Prabodhika R; Ruggiero, Alessandro; Gardner, Jeffrey R et al. (2011) A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res 39:2458-69

Showing the most recent 10 out of 81 publications